New antibody trio takes on Hard-to-Treat lymphoma
NCT ID NCT07308132
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new drug called JNJ-95566692, a trispecific antibody designed to target lymphoma cells. It is given alone or with another drug (JNJ-87801493) to about 130 people whose B-cell non-Hodgkin lymphoma has not responded to or returned after at least two prior treatments. The main goals are to find safe doses and to watch for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JNJ-95566692 (a trispecific antibody) alone or with JNJ-87801493
What this could lead to
If it works, this could lead to a new treatment option for people with B-cell non-Hodgkin lymphoma who have run out of standard therapies.
What could go wrong
This is a very early phase 1 trial, so the main goal is safety, not effectiveness. The treatment may cause serious side effects and may not shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, NON-HODGKIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ankara Universitesi Hastaneleri Tibbi Farmakoloji Anabilim Dali Faz 1 Klinik Arastirma Merkezi
RECRUITINGAnkara, 06620, Turkey (Türkiye)
-
Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman
RECRUITINGLiège, 4000, Belgium
-
Koc Universitesi Hastanesi Faz 1 Klinik Arastirma Merkezi
RECRUITINGIstanbul, 34010, Turkey (Türkiye)
-
Macquarie University Hospital
RECRUITINGNorth Ryde, 2109, Australia
-
Monash Medical Centre
RECRUITINGClayton, 3168, Australia
-
Peter MacCallum Cancer Centre
RECRUITINGMelbourne, 3000, Australia
-
SBU Ankara Dr. Abdurrahman Yurtaslan Onkoloji Egitim ve Arastirma Hastanesi Faz 1 Merkezi
RECRUITINGAnkara, 06200, Turkey (Türkiye)
-
Scientia Clinical Research
RECRUITINGRandwick, 2031, Australia
-
UZ Antwerpen
RECRUITINGEdegem, 2650, Belgium